INO Inovio Pharmaceuticals, Inc.
USHealthcareAs of 2026-07-02
Why INO matters now
Inovio Pharmaceuticals, Inc. (INO) is a US stock in Healthcare. The latest InvestLog snapshot shows $1.22 with +2.52% on the session and $65.4M in market capitalization; recent performance reads 1-month -8.61% and YTD -35.92%.
The latest financial table shown here is Q1 2026, with revenue of $0.00, net income of $-19.7M, and EPS of $-0.28. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -139.9%.
The latest indexable market news headline is "Kuehn Law Encourages Investors of Inovio Pharmaceuticals, Inc. to Contact Law Firm" from PRNewsWire.
Additional event context on this page matters because analyst consensus is Hold with a median target of $2.50; recent insider activity includes Shea Jacqueline Elizabeth filing M-Exempt. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
126.98
P/S
0.00
EV/EBITDA
-0.51
DCF Value
$0.07
FCF Yield
-139.9%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-666.5%
ROA
-170.6%
ROIC
-567.1%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $0.00 | $-19.7M | $-0.28 |
| Q4 2025 | $0.00 | $3.8M | $0.05 |
| FY 2025 | $65.3K | $-84.9M | $-1.81 |
| Q3 2025 | $0.00 | $-45.5M | $-0.87 |
Analyst Ratings
Consensus
Hold
Target (Consensus)
$2.50
Target (Median)
$2.50
Target Range
$2.50 - $2.50
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
US
Exchange
—
Beta
1.49
Inovio Pharmaceuticals, Inc. is a biotechnology firm dedicated to the research, development, and market introduction of DNA-based treatments. Its core mission is to prevent and cure illnesses associated with human papillomavirus (HPV), various types of cancer, and infectious diseases. The company's advanced DNA medicine platform utilizes meticulously engineered SynCon sequences to precisely identify and optimize the genetic blueprint of a target antigen. This innovative approach is supported by its CELLECTRA smart device technology, which efficiently delivers the DNA plasmids. Inovio is actively engaged in and planning clinical trials for its DNA medicines across a wide array of conditions. These include HPV-related precancerous lesions, such as cervical, vulvar, and anal dysplasia; HPV-driven cancers affecting areas like the head and neck, cervix, anus, penis, vulva, and vagina; and other HPV-associated disorders like recurrent respiratory papillomatosis. Beyond HPV, its pipeline addresses glioblastoma multiforme, prostate cancer, and a range of infectious diseases, including HIV, Ebola, Middle East Respiratory Syndrome (MERS), and Lassa fever. The company benefits from a vast network of collaborators and partners, encompassing prominent academic institutions, government agencies, non-profit foundations, and pharmaceutical corporations. Key examples include AstraZeneca, The Bill & Melinda Gates Foundation, the Coalition for Epidemic Preparedness Innovations (CEPI), the Defense Advanced Research Projects Agency (DARPA), the National Institutes of Health, Regeneron Pharmaceuticals, and the University of Pennsylvania. Significant partnerships also involve an agreement with Richter-Helm BioLogics GmbH & Co. KG to further develop the investigational COVID-19 DNA vaccine INO-4800, alongside a strategic alliance with the International Vaccine Institute and Seoul National University Hospital. Established in 1979, Inovio Pharmaceuticals is headquartered in Plymouth Meeting, Pennsylvania.